The risk of extraocular extension from injecting chemotherapy into eyes with retinoblastoma is minimally understood; however, understanding this risk is important because of the increasing use of intravitreous chemotherapy.
H istorically, there has been concern that breaching the wall of an eye with retinoblastoma can result in complications for the eye and the patient. Aspiration techniques in eyes with retinoblastoma have demonstrated tumor within the needle tract. 1 Furthermore, biopsy or intraocular surgery on these diseased eyes has reportedly resulted in reactivation of tumor necessitating enucleation or leading to orbital and/or systemic metastases. 2 In the past, these fears hindered the acceptance of placing any needle, including for drug injection into the vitreous, into an eye with retinoblastoma. However, with the adoption of safety-enhanced techniques, the risk of tumor externalization with intravitreous chemotherapy injections is thought to be low. A meta-analysis by Smith the 95% confidence of a calculated risk of extraocular extension was no greater than 0.08% injections. Numerical details regarding intravitreous injections at each center are given in Table 1 . Across the centers, needle size ranged from 30 to 33 in gauge and 9 to 12 mm in length. Injection site from the limbus ranged from 2.0 to 3.5 mm, and drug volume ranged from 0.04 to 0.20 mL. The dose of injected melphalan hydrochloride ranged from 20 to 40 μg, and if used, 20 μg of topotecan hydrochloride and 400 of μg methotrexate were given. Table 2 gives additional details of the injection method. Cryotherapy was used at the injection site before removal of the needle at all centers. At 7 centers (70%), the IOP was routinely lowered before injection: at 5 centers (40%), paracentesis was used (at 3 of these, higher drug volumes of 0.1-0.2 mL were used); 2 (20%), ocular massage; and 1 (10%), both. At 3 centers (20%), the IOP was not routinely lowered unless 2 drugs were injected or if the IOP was higher than 20 mm Hg. Chemotherapy was injected into the subconjunctival space at only 1 center (10%). At 60 centers (60%), eyes were routinely irrigated after the injection. At most centers, the same entry site was used for repeated injections (7 centers [70%]), ultrasonographic biomicroscopy was performed in eyes with opaque media or absence of mydriasis (7 centers [70%]), and the injection was administered without the use of an operating microscope (6 centers [60%]). At 4 centers (40%), 2 drugs were injected during the same visit, with 2 different needle puncture sites used at all centers. Of the 4 centers in which an operating microscope was used, reflux through the injection site was observed at none. At 1 center (10%), an eye with tumor in the anterior chamber was observed after intravitreous chemotherapy injections; this eye had previous pars plana vitrectomy and cataract extraction with an open posterior capsule. At all centers, at least 2 presumed precautionary measures (cryotherapy, lowering IOP, subconjunctival chemotherapy, ocular surface irrigation, and use of ultrasonographic biomicroscopy) were used, with 3 or more methods used at 8 (80%).
Discussion
To minimize extravasation of tumor at the injection site, a number of centers introduced precautionary practices to lower the risk of extraocular extension, including injecting in a tumorfree location, 6,7 subconjunctival chemotherapy, 8 paracentesis or ocular massage to lower IOP, 6, 7, 9 cryotherapy to needle tract, 9 copious irrigation of the eye, 9 swab to injection site to wipe away vitreous, 7 and histoacryl glue (in eyes undergoing biopsy).
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Some of these techniques were re-established by Munier et al 11 in their 2012 seminal article and are used currently by centers, including those in the present study 12, 13 (Table 2) . Despite the use of these safety-enhancing techniques, questions still exist regarding extraocular extension with intravitreous injections.
Since the resurgence of intravitreous chemotherapy injections in 2012, there have been few dedicated reports on this subject. The studies that exist are limited by small cohorts and use an indirect method (tumor presence in needle of ocular washings) or are restricted to a literature review. 3, 14 Two cases of extraocular tumor extension detected early in the largest cohort worldwide, to our knowledge, from Japan have been reported-the first case with histopathologic confirmation 15 and the second case with extraocular extension that could not exclude intravitreous injection as a contributing factor. 3 The present study more than doubles the published metaanalysis cohort and had no cases of extraocular extension in 3553 injections into 704 eyes of 655 patients. These results come from 4 different continents and 2 World Bank income levels (high and middle income). The study revealed a low risk of extraocular extension with intravitreous chemotherapy in eyes with retinoblastoma. It is unclear which and how many of the precautionary measures contributed to the safety of this technique. Perhaps injecting 2 drugs into an eye involves 2 injections and potentially doubles the risk of a single injection; however, no events of extraocular extension were found in eyes receiving a single or double injection. Finally, it is also unknown whether intravitreous chemotherapy can sterilize the needle tract, and because no events were seen in eyes receiving melphalan alone and topotecan alone, it is unknown whether this possible tract sterilization is associated with the chemotherapy agent used (an alkylating agent vs topoisomerase inhibitor). 
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